PP  Vol.3 No.2 , April 2012
Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature
Abstract: Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) and is characterized by inflammation, demyelination and desctruction of oligodendrocytes and axons. The immunology of MS is complex, involving autoreactive Th1 and Th17 lymphocytes, cells of the innate immune system including dedritic, natural killer (NK) and microglia cells, as well as vascular endothelial cells. Multiple Sclerosis (MS) is based by a series of biochemical changes affecting to different extent neuronal functions; great attention has been focused on: liver enzymes, thyroid function tests, autoantibodies, lipid profile and uric acid levels. Following the introduction of therapy with drugs that modify the course of disease, more attention has been paid to the change of biochemical parameters, in particular to evaluate possible adverse effects. Aim of this study was to perform a review of the literature on biochemical alterations in treated and untreated MS patients and to assess laboratory parameters alterations in a cohort of MS patients, before and during treatment. On a total of 624 patients followed at our center, we selected those who practiced for the first time a therapy with IFN beta 1a at various doses, IFN beta 1b and Glatiramer acetate, that were 595 (95%), with baseline biochemical evaluation available in 488 (82%) (307 females, mean age 36.6 years). We considered the evolution of various biochemical parameters during treatment. The following outcome variables were evaluated: laboratory changes, in particular liver function, thyroid function, lipids and blood cell count. Percentages were compared using the chisquare test. ANOVA was performed to evaluate changes of laboratory tests over time between therapy groups. Our finding confirm the presence of biochemical alterations at baseline, in particular regarding liver enzymes, thyroid hormones and lipids. Treatment effects were more evident on liver enzymes elevation, anti thyroid antibodies production and blood cholesterol decrease. These effects were mainly transient and self remitting without suspension of therapy. Biochemical alterations, mainly related to autoimmune pathology and lipid metabolism change were encountered. Treatments increased transient biochemical alterations particulary in patients with baseline changes, suggesting a stricter monitoring of blood exams in this category of patients.
Cite this paper: N. Salvatore Orefice, O. Ferraro, F. Barbato, A. Carotenuto, R. Lanzillo, V. Brescia Morra, G. Coppola and G. Orefice, "Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature," Pharmacology & Pharmacy, Vol. 3 No. 2, 2012, pp. 248-253. doi: 10.4236/pp.2012.32033.

[1]   J. H. Noseworthy, “Progress in Determing the Causes and Treatment of Multiple Sclerosis,” Nature, Vol. 399, 1999, pp. A40-A47.

[2]   L. Steinman, “Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System,” Cell, Vol. 85, No. 3, 1996, pp. 229-302

[3]   M. Tiberio, D. T. Chard, G. R. Altmann, et al., “Metabolite Changes in Early Relapsing-Remitting Multiple Sclerosis. A Two Year Follow-Up Study,” Journal of Neurology, Vol. 253, No. 2, 2006, pp. 224-230

[4]   C. Behl, “Oxidative Stress in Alzheimer’s Disease: Implications for Prevention and Therapy,” Sub-Cellular Biochemistry, Vol. 38, 2005, pp. 65-78. doi:10.1007/0-387-23226-5_3

[5]   Z. Gu, T. Nakamura, D. Yao, Z. Q. Shi, et al., “Nitrosative and Oxidative Stress Links Dysfunctional Ubiquitination to Parkinson’s Disease,” Cell Death and Differentiation, Vol. 12, No. 9, 2005, pp. 1202-1204. doi:10.1038/sj.cdd.4401705

[6]   H. Tremlett and J. Oger, “Hepatic Injury, Liver Monitoring and the Be-ta-Interferons for Multiple Sclerosis,” Journal of Neurology, Vol. 251, No. 11, 2004, pp. 1297- 1303. doi:10.1007/s00415-004-0619-5

[7]   L. Durelli, B. Ferrero, A. Oggero, et al., “Betaferon Safety Trial (BEST) Study Group. Liver and Thyroid Function and Autoimmunity during Interferon-Beta 1b Treatment for MS,” Neurology, Vol. 57, No. 8, 2001, pp. 1363-1370.

[8]   G. Niederwieser, W. Buchinger, R. M. Bonelli, et al., “Prevalence of Autoimmune Thyroiditis and Non-Immune Thyroid Disease in Multiple Sclerosis,” Journal of Neurology, Vol. 250, No. 6, 2003, pp. 672-675. doi:10.1007/s00415-003-1053-9

[9]   F. Giubilei, G. Antonini, S. Di Legge, et al., “Blood Cholesterol and MRI Activity in First Clinical Episode Suggestive of Multiple Sclerosis,” Acta Neurologica Scandinavica, Vol. 106, No. 2, 2002, pp. 109-112. doi:10.1034/j.1600-0404.2002.01334.x

[10]   S. Sotgiu, M. Pugliatti, A. Sanna, et al., “Serum Uric Acid and Multiple Sclerosis,” Neurological Sciences, Vol. 23, No. 4, 2002, pp. 183-188. doi:10.1007/s100720200059

[11]   G. Toncev, B. Milicic, S. Toncev, et al., “Serum Uric Acid Levels in Multiple Sclerosis Patients Correlate with Activity of Disease and Blood-Brain Barrier Dysfunction,” European Journal of Neurology, Vol. 9, No. 3, 2002, pp. 221-226. doi:10.1046/j.1468-1331.2002.00384.x

[12]   G. Toncev, B. Milicic, S. Toncev and G. Samardzic, “High-Dose Methylprednisolone Therapy in Multiple Sclerosis Increases Serum Uric Acid Levels,” Clinical Chemistry and Laboratory Medicine, Vol. 40, No. 5, 2002, pp. 505-508.

[13]   T. Vial and J. Descotes, “Clinical Toxicity of the Interferons,” Drug Safety, Vol. 10, No. 2, 1994, pp. 115-150. doi:10.2165/00002018-199410020-00003

[14]   F. Mon-zani, N. Caraccio, A. Casolaro, F. Lombardo, G. Moscato, L. Murri, E. Ferrannini and G. Meucci, “Long-Term Interferon Beta-1b Therapy for MS: Is Routine Thyroid Assessment Always Useful,” Neurology, Vol. 55, No. 4, 2000, pp. 549-552.

[15]   P. Rieckmann, P. O’Connor, G. S. Francis, G. Wetherill and E. Alteri, “Haematological Effects of Interferon-Beta-1a (Rebif) Therapy in Multiple Sclerosis,” Drug Safety, Vol. 27, No. 10, 2004, pp. 745-756. doi:10.2165/00002018-200427100-00005

[16]   P. V. Byskosh and A. T. Reder, “Interferon Beta-1b Effects on Cytokine mRNA in Peripheral Mononuclear Cells in Multiple Sclerosis,” Multiple Sclerosis, Vol. 1, No. 5, 1996, pp. 262-269.

[17]   C. S. Constantinescu, P. Freitag and L. Kappos, “Increase in Serum Levels of Uric Acid, an Endogenous Antioxidant, under Treatment with Glatiramer Acetate for Multiple Sclerosis,” Multiple Sclerosis, Vol. 6, No. 6, 2000, pp. 378-381.

[18]   V. B. Morra, G. Coppola, G. Orefice, et al., “Interferon- Beta Treatment Decreases Cholesterol Plasma Levels in Multiple Sclerosis Patients,” Neurology, Vol. 62, No. 5, 2004, pp. 829-830.

[19]   G. Coppola, R. Lanzillo, C. Florio, et al., “Long-Term Clinical Experience with Weekly Interferon Beta-1a in Relapsing Multiple Sclerosis,” European Journal of Neurology, Vol. 13, No. 9, 2006, pp. 1014-1021. doi:10.1111/j.1468-1331.2006.01422.x

[20]   R. W. Baker, H. Sanders, R. H. Thompson, et al., “Serum Cholesterol Linoleate Levels in Multiple Sclerosis,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 28, No. 3, 1965, pp. 212-217

[21]   F. Lolli, B. Mazzanti, M. Pazzagli, et al., “The Glycopeptide CSF114 (Glc) Detects Serum Antibodies in Multiple Sclerosis,” Journal of Neuroimmunology, Vol. 167, No. 1-2, 2005, pp. 131-137. doi:10.1016/j.jneuroim.2005.05.016

[22]   R. Lanzillo, G. Orefice, M. Quarantelli, et al., “Atorvastatin Combined to Interferon to Verify the Efficacy (ACTIVE) in Relapsing Remitting Active Multiple Sclerosis Patients: A Longitudinal Controlled Trial of Combination Therapy,” Multiple Sclerosis, Vol. 16, No. 4, 2010, pp. 450-454. doi:10.1177/1352458509358909

[23]   M. Togha, S. A. Karvigh, M. Nabavi, et al., “Simvastatin Treatment in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta 1a: A Double-Blind Randomized Controlled Trial,” Multiple Sclerosis, Vol. 16, No. 7, 2010, pp. 848-854. doi:10.1177/1352458510369147